Carmustine-impregnated wafers and their impact in the management of high-grade glioma. (Q55463110)

12 July 2018

title

Carmustine-impregnated wafers and their impact in the management of high-grade glioma. (English)

1 reference

12 July 2018

author name string

Renato V La Rocca

series ordinal

1

1 reference

12 July 2018

Arash Rezazadeh

series ordinal

2

1 reference

12 July 2018

language of work or name

English

0 references

publication date

1 June 2011

1 reference

12 July 2018

Expert Opinion on Pharmacotherapy

published in

1 reference

12 July 2018

volume

12

1 reference

12 July 2018

issue

8

1 reference

12 July 2018

page(s)

1325-1332

1 reference

12 July 2018

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Stud

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Intratumoral doxorubicin in patients with malignant brain gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Convection-enhanced delivery of macromolecules in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Polymer delivery of chemotherapy for squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Chemoradiotherapy in malignant glioma: standard of care and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.580737

10.1517/14656566.2011.580737

21 January 2018

Identifiers

DOI

1 reference

12 July 2018

1 reference

12 July 2018